Showing papers in "Seminars in Oncology in 2003"

TL;DR: This presentation represents consensus recommendations for the clinicopathological definition of Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the Second International Workshop held in Athens, Greece during September 2002.

TL;DR: The optimal dose of bevacizumab in this trial was 10 mg/kg every other week and toxicity was acceptable, and these data support the initiation of trials in metastatic breast cancer combining bevacszumab with chemotherapy.

TL;DR: A recursive partitioning analysis of three Radiation Therapy Oncology Group trials showed that among patients under 50 years of age, astrocytoma with anaplastic or atypical foci was associated with significantly improved survival compared with glioblastoma, suggesting that mental status may be a more important determinant of clinical outcome than physical functioning in patients with high-grade glioma.

TL;DR: ZD1839 (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, DE) is the EGFR-TK inhibitor furthest along in clinical development, and it is currently being investigated in a variety of solid tumors, including non-small-cell lung cancer.

TL;DR: The predictability of neurotoxicity associated with oxaliplatin-based therapy should allow patients and doctors to develop strategies to manage this side effect in view of the individual patient's clinical situation.

TL;DR: The consensus panel agreed that initiation of therapy was appropriate for patients with constitutional symptoms such as recurrent fever, night sweats, fatigue due to anemia, or weight loss and called for studies on the application of prognostic markers in WM.

TL;DR: CI-1040 (PD184352) is an orally active, highly specific, small-molecule inhibitor of one of the key components of this pathway (MEK1/MEK2), and thereby effectively blocks the phosphorylation of ERK and continued signal transduction through this pathway.

TL;DR: The current understanding of the mechanisms of rituximab cell killing is reviewed, including complement-dependent cytoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis in the light of the latest clinical and preclinical data.

TL;DR: Several HER1/EGFR-targeted agents are advanced in clinical development and attention is focused on optimizing their clinical use, suggesting that this process may prove challenging, but promises to be beneficial.

TL;DR: The current status of MTA biochemistry is reviewed and it is suggested that MTA1 may play a role in both the physiologic and the pathologic states of cells.

TL;DR: A brief review on the strategy and recent progress in designing small-molecule antagonists targeting B cl-2 and Bcl-X(L), a very new and exciting area for current anticancer drug design and development.

TL;DR: J591 as mentioned in this paper is the first IgG mAb developed to target the extracellular domain of PSMA, and it has been deimmunized (humanized) to allow repeated dosing in patients.

TL;DR: The literature documents that the majority of breast cancer survivors have adjusted well after their first 2 years since diagnosis, but there is a subset of survivors reporting psychological distress, including depression and anxiety, involving approximately 30% by 4 years post-treatment, however, a large proportion of survivors report cancer-related problems long after treatment completion.

TL;DR: The latest aromatase inhibitors are drugs of immense potential that will undoubtedly play a major role in the management of postmenopausal women with hormone-dependent breast cancer and represent tools by which to elucidate the roles of both aromat enzyme and estrogen in the development and growth of breast cancer.

TL;DR: In murine models of prostate cancer, 17-AAG causes the degradation of proteins that require this chaperone for maturation or stability at nontoxic doses and inhibits the growth of hormone-naive and castration-resistant tumors.

TL;DR: This work has explored the antigenic characteristics of both the plasma cell (PC) and mast cell (MC) compartments present in the BM from 15 WM patients and identified the coexistence of two different clones of B lymphocytes was identified, and intraclonal phenotypic heterogeneity was observed.

TL;DR: The management of osteopenia and osteoporosis in women with breast cancer generally does not differ from women without breast cancer, andequate dietary calcium and vitamin D intake, encouraging weight-bearing exercise, and counseling about the relationship between smoking and alcohol and bone loss are all prudent recommendations for overall health and may lessen bone loss and the risk of subsequent osteopsorosis.

TL;DR: This review will focus on the signaling network mediated by HER2/neu in breast cancer and discuss the understanding of these pathways, which seem to be particularly important in mediating cell survival and growth under a wide variety of circumstances in Breast cancer.

TL;DR: The conceptual basis of anti-angiogenic therapy is outlined, the critical role of vascular endothelial growth factor is discussed, and the available data on the use of bevacizumab in colorectal cancer is summarized.

TL;DR: Preliminary data suggest that PTK/ZK can be administered safely on a continuous daily dosing schedule, efficacy data look promising, and DCE-MRI correlates with biological response.

TL;DR: In limited disease, however, cisplatin plus etoposide alone or in alternation with cyclophosphamide/doxorubicin/vincristine is superior to other approaches.

TL;DR: Clinical trials show that antigen-loaded dendritic cell vaccinations are safe and promising in the treatment of cancer, including non-Hodgkin lymphoma, multiple myeloma, prostate cancer, malignant melanoma, colorectal cancer, and non-small cell lung cancer.

TL;DR: CI-1033 is a highly potent and selective pan-erbB inhibitor that efficiently blocks signal transduction through all four members of the erbB receptor family, and covalently binds to these receptors, irreversibility inhibiting them, and thereby provides for prolonged suppression of erb B receptor-mediated signaling.

TL;DR: This presentation represents consensus recommendations for the treatment of patients with Waldenstrom's macroglobulinemia, which were prepared in conjunction with the second International Workshop held in Athens, Greece during September 2002.

TL;DR: Identification of subtypes of ALL with different prognosis and treatment requirements offers the potential to improve management and survival in ALL.

TL;DR: The results of a recent cross-sectional study involving 195 patients with low-grade gliomas strongly suggest that standard focal RT with fractional doses less than 2 Gy is not generally associated with an increased risk of cognitive deficits, but that higher fractions are likely to result in cognitive disability.

TL;DR: Preclinical data provide a strong rationale for investigating erlotinib in the clinical setting, however, additional studies are required to gain further insights into the processes that regulate or influence the antitumor activity of erlot inib.

TL;DR: 90 consecutive, previously untreated patients with symptomatic WM using either 2-CdA alone or in combination with other agents including prednisone (pred), cyclophosphamide (Cy), and rituximab (Rit) are treated, supporting the potential role of 2- CdA regimens as the treatment of choice for previously untreated WM.

TL;DR: Phase I pharmacokinetic studies show that treatment with erlotinib HCl, an orally available epidermal growth factor receptor (HER1/EGFR)-tyrosine kinase inhibitor, on a daily, uninterrupted schedule is feasible, and studies indicate that skin may be a useful surrogate tissue for evaluating the pharmacodynamic effects of therapy.

TL;DR: Erlotinib HCI (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available quinazoline-based agent that competes with adenosine triphosphate for binding with the intracellular catalytic domain of epidermal growth factor receptor (HER1/EGFR) tyrosine kinase, inhibiting phosphorylation as discussed by the authors.